2022
DOI: 10.1186/s12967-022-03808-7
|View full text |Cite
|
Sign up to set email alerts
|

Kinin B1 receptor blockade attenuates hepatic fibrosis and portal hypertension in chronic liver diseases in mice

Abstract: Background and aims Kinin B1 receptors (B1Rs) are implicated in the pathogenesis of fibrosis. This study examined the anti-fibrotic effects of B1R blockade with BI 113823 in two established mouse models of hepatic fibrosis induced by intraperitoneal carbon tetrachloride (CCl4) injection or bile duct ligation (BDL). The mechanisms underlying the protection afforded by B1R inhibition were examined using human peripheral blood cells and LX2 human hepatic stellate cells (HSCs). … Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1

Citation Types

0
1
0

Year Published

2023
2023
2024
2024

Publication Types

Select...
6

Relationship

0
6

Authors

Journals

citations
Cited by 6 publications
(2 citation statements)
references
References 41 publications
0
1
0
Order By: Relevance
“…A therapy using Bradykinin 1 receptor antagonist (BI 113823), the main inhibitor of Kinin B1 receptors (B1Rs), has been shown to reduce the expression of both CTGF and TGF-β in vivo. Additionally, the results of this study confirmed that BI 113823 inhibits the activation of HSC as its activation is originally stimulated by both TGF-β and B1R agonists [79]. Therefore, as HSCs are the main CTGF-producing cells, they show great potential as promising targets for the future treatment of liver fibrosis.…”
Section: Inhibition Of the Ecm Production And Promotion Of Ecm Degrad...supporting
confidence: 68%
“…A therapy using Bradykinin 1 receptor antagonist (BI 113823), the main inhibitor of Kinin B1 receptors (B1Rs), has been shown to reduce the expression of both CTGF and TGF-β in vivo. Additionally, the results of this study confirmed that BI 113823 inhibits the activation of HSC as its activation is originally stimulated by both TGF-β and B1R agonists [79]. Therefore, as HSCs are the main CTGF-producing cells, they show great potential as promising targets for the future treatment of liver fibrosis.…”
Section: Inhibition Of the Ecm Production And Promotion Of Ecm Degrad...supporting
confidence: 68%
“…Tang et al [ 44 ] demonstrated that inhibiting STAT3 by siRNA or antisense oligonucleotide (ASO) had a therapeutic role in CCl 4 ‐induced liver fibrosis model. As Rampa et al [ 45 ] elegantly showed that blocking Kinin B1 receptor attenuated hepatic fibrosis in bile duct ligation models by regulating the activation of PI3K/AKT signaling pathway. A number of drugs are in development for these pathways and targets.…”
Section: Discussionmentioning
confidence: 99%